Publication Name	World Journal of Gastroenterology
Manuscript ID	5744
Country	Japan

Received	2013-09-25 09:18
Peer-Review Started	2013-09-25 11:54
To Make the First Decision	2013-10-29 12:30
Return for Revision	2013-10-16 13:05
Revised	2013-10-23 23:12
Second Decision	2014-01-15 20:20
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-01-15 20:35
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-03-04 09:33
Publish the Manuscript Online	2014-03-18 14:14

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Hepatitis C virus NS5A inhibitors and drug resistance mutations
Manuscript Source	Invited Manuscript
All Author List	Shingo Nakamoto, Tatsuo Kanda, Shuang Wu, Hiroshi Shirasawa and Osamu Yokosuka
Funding Agency and Grant Number	Funding Agency Grant Number Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan to Nakamoto S, Kanda T Ministry of Health, Labour, and Welfare of Japan to Yokosuka O
Corresponding Author	Tatsuo Kanda, MD, PhD, Associate Professor, Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. kandat-cib@umin.ac.jp
Key Words	ACH-3102; Direct-acting antiviral agents; Daclatasvir; Hepatitis C virus; Ledipasvir
Core Tip	Hepatitis C virus (HCV) NS5A inhibitors such as daclatasvir and ledipasvir in combination with other direct-acting antiviral agents against other regions of HCV with or without peginterferon/ribavirin are becoming available for daily clinical practice. These inhibitors can induce resistance mutations more easily in HCV genotype 1a patients than in HCV genotype 1b patients. HCV NS5A inhibitors should be used in combination regimens potent enough to prevent the emergence of resistant mutants and attention should be paid to these mutants’ potential emergence.
Publish Date	2014-03-18 14:14
Citation	Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014; 20(11): 2902-2912
URL	http://www.wjgnet.com/1007-9327/full/v20/i11/2902.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i11.2902

Full Article (PDF)	WJG-20-2902.pdf
Full Article (Word)	WJG-20-2902.doc
Manuscript File	5744-Review.doc
Answering Reviewers	5744-Answering reviewers.pdf
Copyright License Agreement	5744-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	5744-Language certificate.pdf
Peer-review Report	5744-Peer reviews.pdf
Scientific Editor Work List	5744-Scientific editor work list.doc